These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26435454)

  • 1. Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions.
    Delplace V; Payne S; Shoichet M
    J Control Release; 2015 Dec; 219():652-668. PubMed ID: 26435454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.
    Agrahari V; Agrahari V; Mandal A; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 Oct; 14(10):1145-1162. PubMed ID: 27967247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology approaches for ocular drug delivery.
    Xu Q; Kambhampati SP; Kannan RM
    Middle East Afr J Ophthalmol; 2013; 20(1):26-37. PubMed ID: 23580849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanotechnology in ocular delivery: current and future directions.
    Sultana Y; Maurya DP; Iqbal Z; Aqil M
    Drugs Today (Barc); 2011 Jun; 47(6):441-55. PubMed ID: 21695286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in ocular drug delivery.
    Achouri D; Alhanout K; Piccerelle P; Andrieu V
    Drug Dev Ind Pharm; 2013 Nov; 39(11):1599-617. PubMed ID: 23153114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies.
    Kannan RM; Pitha I; Parikh KS
    Adv Drug Deliv Rev; 2023 Sep; 200():115005. PubMed ID: 37419213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intractable Ocular Diseases and Treatment Progress.
    Zhang X; Li S; Tang Y; Guo Y; Gao S
    AAPS PharmSciTech; 2020 Aug; 21(6):236. PubMed ID: 32803351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
    Qi Q; Wei Y; Zhang X; Guan J; Mao S
    J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of Exosomes in Ocular Diseases.
    Liu J; Jiang F; Jiang Y; Wang Y; Li Z; Shi X; Zhu Y; Wang H; Zhang Z
    Int J Nanomedicine; 2020; 15():10519-10538. PubMed ID: 33402823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
    Cheng KJ; Hsieh CM; Nepali K; Liou JP
    J Med Chem; 2020 Oct; 63(19):10533-10593. PubMed ID: 32482069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
    Babizhayev MA
    Drug Test Anal; 2012 Jun; 4(6):468-85. PubMed ID: 21416634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current ocular drug delivery challenges for N-acetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships.
    Babizhayev MA
    Recent Pat Drug Deliv Formul; 2009 Nov; 3(3):229-65. PubMed ID: 19534670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in ocular drug delivery: emphasis on the posterior segment.
    Kang-Mieler JJ; Osswald CR; Mieler WF
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New techniques for drug delivery to the posterior eye segment.
    Eljarrat-Binstock E; Pe'er J; Domb AJ
    Pharm Res; 2010 Apr; 27(4):530-43. PubMed ID: 20155388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable hydrogels based on biopolymers for the treatment of ocular diseases.
    Yu C; Xu J; Heidari G; Jiang H; Shi Y; Wu A; Makvandi P; Neisiany RE; Zare EN; Shao M; Hu L
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132086. PubMed ID: 38705321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ophthalmic drug discovery.
    Clark AF; Yorio T
    Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmic drug delivery considerations at the cellular level: drug-metabolising enzymes and transporters.
    Attar M; Shen J; Ling KH; Tang-Liu D
    Expert Opin Drug Deliv; 2005 Sep; 2(5):891-908. PubMed ID: 16296785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for Polymers Used in Ocular Drug Delivery.
    Allyn MM; Luo RH; Hellwarth EB; Swindle-Reilly KE
    Front Med (Lausanne); 2021; 8():787644. PubMed ID: 35155469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.